Comparative Pharmacology
Head-to-head clinical analysis: AVC versus SULF 15.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVC versus SULF 15.
AVC vs SULF-15
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVC (sulfanilamide) is a sulfonamide antibiotic that inhibits bacterial dihydrofolate synthesis by competing with para-aminobenzoic acid (PABA), thereby blocking folic acid production and bacterial growth.
SULF-15 is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels (K_ATP), leading to cell membrane depolarization, calcium influx, and exocytosis of insulin.
1 applicatorful (approximately 5 g of 0.1% cream) intravaginally once daily at bedtime for 7 days.
150 mg orally twice daily for 14 days.
None Documented
None Documented
3-5 hours; prolonged in renal impairment (up to 12 hours).
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to >30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 30-50% unchanged; biliary/fecal: 10-20% as metabolites.
Renal excretion accounts for 60-70% of elimination as unchanged drug; biliary/fecal excretion accounts for 20-30% as metabolites and parent compound.
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)